Unraveling the multifaceted insights into amyotrophic lateral sclerosis: Genetic underpinnings, pathogenesis, and therapeutic horizons

Nov 4, 2024Mutation research. Reviews in mutation research

Understanding Amyotrophic Lateral Sclerosis: Genes, Disease Causes, and Possible Treatments

AI simplified

Gut-Brain Axis on OpenScience ↗PubMed ↗DOI ↗

Abstract

ALS affects 1.5 to 3.8 per 100,000 individuals globally, primarily impacting those aged 45-80.

ALS is characterized by the degeneration of upper and lower motor neurons, leading to motor dysfunction and respiratory failure.
Key genetic factors linked to ALS include mutations in the C9ORF72, SOD1, FUS, and TARDBP genes, affecting both familial and sporadic cases.
The disease mechanism involves protein misfolding, mitochondrial issues, oxidative stress, excitotoxicity, and neuroinflammation, all contributing to neuron death.
Environmental factors, such as toxins and heavy metals, interact with genetic predispositions to influence the risk and progression of ALS.
Current diagnostic methods for ALS are limited, relying on symptom presentation and family history due to the absence of specific biomarkers.
Therapeutic approaches are in early development stages, focusing on symptomatic management and experimental strategies targeting molecular pathways relevant to ALS.

AI simplified

Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease, primarily impairs upper and lower motor neurons, leading to debilitating motor dysfunction and eventually respiratory failure, widely known as Lou Gehrig's disease. ALS presents with diverse symptomatology, including dysarthria, dysphagia, muscle atrophy, and hyperreflexia. The prevalence of ALS varies globally, with incidence rates ranging from 1.5 to 3.8 per 100,000 individuals, significantly affecting populations aged 45-80. A complex interplay of genetic and environmental factors underpins ALS pathogenesis. Key genetic contributors include mutations in chromosome 9 open reading frame 72 (C9ORF72), superoxide dismutase type 1 (SOD1), Fusedin sarcoma (FUS), and TAR DNA-binding protein (TARDBP) genes, accounting for a considerable fraction of both familial (fALS) and sporadic (sALS) cases. The disease mechanism encompasses aberrant protein folding, mitochondrial dysfunction, oxidative stress, excitotoxicity, and neuroinflammation, contributing to neuronal death. This review consolidates current insights into ALS's multifaceted etiology, highlighting the roles of environmental exposures (e.g., toxins, heavy metals) and their interaction with genetic predispositions. We emphasize the polygenic nature of ALS, where multiple genetic variations cumulatively influence disease susceptibility and progression. This aspect underscores the challenges in ALS diagnosis, which currently lacks specific biomarkers and relies on symptomatology and familial history. Therapeutic strategies for ALS, still in nascent stages, involve symptomatic management and experimental approaches targeting molecular pathways implicated in ALS pathology. Gene therapy, focusing on specific ALS mutations, and stem cell therapy emerge as promising avenues. However, effective treatments remain elusive, necessitating a deeper understanding of ALS's genetic architecture and the development of targeted therapies based on personalized medicine principles. This review aims to provide a comprehensive understanding of ALS, encouraging further research into its complex genetic underpinnings and the development of innovative, effective treatment modalities.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Unraveling the multifaceted insights into amyotrophic lateral sclerosis: Genetic underpinnings, pathogenesis, and therapeutic horizons

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the gut-brain axis brief